Intrathecal Antibacterial and Antifungal Therapies | Zendy

Roland Nau | Zendy; Claudia Blei | Zendy; Helmut Eiffert | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Intrathecal Antibacterial and Antifungal Therapies

Author(s) -

Roland Nau,

Claudia Blei,

Helmut Eiffert

Publication year - 2020

Publication title -

clinical microbiology reviews

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 9.177

H-Index - 282

eISSN - 1070-6305

pISSN - 0893-8512

DOI - 10.1128/cmr.00190-19

Subject(s) - intrathecal , medicine , colistin , antibiotics , cerebrospinal fluid , daptomycin , vancomycin , tigecycline , toxicity , pharmacology , antifungal , anesthesia , microbiology and biotechnology , staphylococcus aureus , bacteria , biology , genetics , dermatology

Intrathecal administration of anti-infectives is indicated in central nervous system infections by multiresistant pathogens when drugs that can reach adequate cerebrospinal fluid (CSF) concentrations by systemic therapy are not available. Antibiotics that readily pass the blood-brain and blood-CSF barriers and/or that have low toxicity allowing an increase in the daily dosage should not be used for intrathecal therapy. Intrathecal therapy is accompanied by systemic treatment. Antibacterials indispensable for intrathecal therapy include aminoglycosides, colistin, daptomycin, tigecycline, and vancomycin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research